MC2TCN
  • Nanotech & Cancer Treatment

    Nanotech & Cancer Treatment

    People of the Center
    The people who make The Center what it is today.
    Collaborations
    Our collaborations with other related organizations.
    Our Facilities
    The facilities at the Center.
    Research Areas
    Research areas at the Center.
  • Research Projects
  • Resources

    Resources

    Publications
    Publications by our leaders and staff.
    Clinical Trials
    Clinical Trials related to our Research Projects.
    Seminars & Events
    Seminars & Events related to our work.
    FAQ
    Frequently asked questions about the Center.
    News
    News related to the Center and our work.
  • Contact Us
  1. Home
  2. Research Projects
  3. Targeted Ultrasmall Silica Nanoparticles for Alpha- and Beta-Emitting Radiotherapy

Targeted Ultrasmall Silica Nanoparticles for Alpha- and Beta-Emitting Radiotherapy

The primary objectives of translational research Project 3 are to (1) target radiolabeled C dots to melanoma to deliver highly localized radiation doses and (2) deliver and release SMIs from nanoparticle-drug conjugates (NDCs) to malignant brain tumors.

Melanoma studies will be led by Thomas Quinn, Professor of Biochemistry, University of Missouri, with co-lead Michael McDevitt, Radiologist, MSKCC. Major goals for melanoma models include the generation of optimized targeted C dots exhibiting favorable biological properties in melanoma models, as well as the development of safe and efficacious alpha- and beta-emitting C dots for clinical translation. Expected outcomes include the advancement of targeted C dot radiotherapeutics as part of combinatorial treatment paradigms with immunotherapies to improve melanoma management. Major goals of the malignant brain tumor studies, led by Cameron Brennan, M.D., Associate Member, Human Oncology and Pathogenesis Program, Sloan Kettering Institute, and Associate Professor of Neurosurgery, Weill Cornell Medical Center with co-lead Charles Rudin, M.D., Ph.D., Chief, Thoracic Oncology, MSKCC, will include the creation of optimized NDCs that exhibit favorable biological properties and overcome dose-limiting toxicity for use in combinatorial brain tumor treatment strategies. Expected outcomes include the development of potent NDCs with improved PK profiles, tumor accumulation, and enhanced therapeutic index.​

Team Leader
Michelle Bradbury

Principal Investigator, Co-Director

Director, Intraoperative Imaging & Co-Chair Innovations Technology Team

Memorial Sloan Kettering

Previous Project

Real-time Intraoperative Imaging of Cancer Biomarkers and Peripheral...

Next Project

Targeted Ultrasmall Silica Nanoparticles for Delivery of Small...

Recent Resources
View All
Clinical Trials
Image-Guided Stereotactic Biopsy of High Grade Gliomas
Clinical Trials
Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast, and Gynecologic Malignancies
Publications
Molecular MR Imaging in Oncology
By Michelle Bradbury, MD, PhD, and Hedvig Hricak, MD, PhD

Partners

  • Memorial Sloan Kettering Cancer Center
  • Cornell University
  • National Cancer Institute

MC2TCN PODCAST

Listen to our latest podcast series.

Keep Up To Date

  • FAQ
  • Privacy & Terms
  • Sitemap
  • © 2017 MSK-Cornell Center for Translations of Cancer Nanomedicine
  • New York Web Design by Avatar New York